Efficient elimination of pancreatic cancer stem cells by hedgehog/GLI inhibitor GANT61 in combination with mTOR inhibition by unknown
RESEARCH Open Access
Efficient elimination of pancreatic cancer
stem cells by hedgehog/GLI inhibitor
GANT61 in combination with mTOR
inhibition
Yumi Miyazaki1, Shyuichirou Matsubara1, Qiang Ding1, Koichiro Tsukasa1, Makoto Yoshimitsu2,
Ken-ichiro Kosai3 and Sonshin Takao1,4*
Abstract
Background: Pancreatic cancer is one of the most lethal malignancies. The innovative treatments are required
and now the cancer stem cells (CSCs) are expected to be an effective target for novel therapies. Therefore
we investigated the significance of hedgehog (Hh) signaling in the maintenance of CSC-like properties of
pancreatic cancer cells, in order to discover the key molecules controlling their unique properties.
Methods: Human pancreatic cancer cell lines, Capan-1, PANC-1, MIA PaCa-2 and Capan-1 M9 were used
for our experiments in DMEM/F12 medium containing 10 % fetal bovine serum. Sphere formation assay,
immunofluorescence staining, flow cytometric analysis and MTT cell viability assay were performed to
investigate molecular signals and the efficacy in the treatment of pancreatic cancer cells.
Results: Inhibition of the Hh pathway significantly reduced the expression of stem cell marker CD133 and sphere
formation, an index of self-renewal capacity, demonstrating the suppression of CSC-like properties. Moreover, the GLI
inhibitor GANT61 induced greater reduction in sphere formation and cell viability of pancreatic cancer cells than the
smoothened (SMO) inhibitor cyclopamine. This suggests that GLI transcription factors, but not SMO membrane protein,
are the key molecules in the Hh pathway. The treatment using GANT61 in combination with the inhibition of mTOR,
which is another key molecule in pancreatic CSCs, resulted in the efficient reduction of cell viability and
sphere formation of an inhibitor-resistant cell line, showing the strong efficacy and wide range applicability
to pancreatic CSC-like cells.
Conclusions: Thus, this novel combination treatment could be useful for the control of pancreatic cancer
by targeting pancreatic CSCs. This is the first report of the efficient elimination of pancreatic cancer stem-like
cells by the double blockage of Hh/GLI and mTOR signaling.
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Background
Pancreatic cancer is one of the most lethal malignancies
which the average overall 5-year survival is around 5 %
[1]. Therefore, the need for innovative treatments re-
mains urgent. Over the last decade, the cancer stem cell
(CSC) hypothesis has developed [2, 3], and is attractive
because it may explain the poor prognosis of pancreatic
cancer patients.
Pancreatic CSCs have unique functions, including self-
renewal, hierarchical proliferation, and “differentiation”
into non-self-renewing bulk tumor cells [2, 3]. Further,
these CSCs are thought to be correlated with metastasis,
chemo- and radio-resistance, and alteration of adjacent
stromal cells [4]. Pancreatic CSCs can be distinguished
from bulk tumor cells based on their expression of
unique surface markers, which include CD133 [2] or a
combination of CD44/CD24/EpCAM [3]; their ability to
form spheres under non-adherent stem cell culture con-
ditions; and their conclusive ability to form metastases
in immunodeficient mice [5].
We recently reported that the mammalian target of
rapamycin (mTOR) plays critical roles in maintaining
pancreatic CSCs [6], indicating that mTOR may be a
promising target to eliminate pancreatic CSCs. In
addition, we found that cyclopamine, an inhibitor of the
hedgehog (Hh) pathway, significantly reduced the con-
tent (percentage) of CD133+ cells in a pancreatic cancer
cell population. This result indicates that the Hh path-
way is another potential target to eliminate pancreatic
CSCs. Aberrant expression of the Hh ligand is observed
at a high frequency in pancreatic cancer and is detect-
able throughout disease progression [7] because pancre-
atic CSCs have been reported to express elevated level of
the Hh ligand [3].
Activation of the canonical Hh signaling pathway is
initiated by the binding of Hh ligands, such as sonic
hedgehog (SHH), to the transmembrane receptor
patched (PTC). This activates another transmembrane
signaling molecule smoothened (SMO). Subsequently
SMO activates the final mediator of Hh signaling, the
GLI family of transcription factors. The activation of
GLI family results in the expression of Hh target genes
[7]. Blockage of Hh signaling has been examined to pre-
vent disease progression and metastatic spread using
predominantly Hh/SMO signaling (i.e., Hh signaling at
the level of the SMO transmembrane molecule) inhibi-
tors. However, these inhibitors were not so effective for
many cancers in which Hh ligand overexpression is con-
sidered to drive tumor growth [8]. The efficacy of the
Hh/SMO signaling inhibitors on pancreatic cancer is still
in dispute.
A small molecule inhibitor of GLI1 and GLI2, the Gli
ANTagonist (GANT61), was recently identified. This
molecule acts in the nucleus to block GLI1- and GLI2-
mediated transcription, and shows a high specificity for
Hh signaling [9]. We applied this molecule to treat
pancreatic CSC-like cells and found that targeting Hh/
GLI signaling (i.e., Hh signaling at the level of the GLI
transcription regulator) effectively reduces CSC-like
properties. Based on these results, we investigated the
efficacy of combination treatment of GANT61 and the
mTOR inhibitor (rapamycin) to pancreatic cancer cell
lines. This is the first report indicating the effective and
powerful elimination of pancreatic CSCs by blockage of
both Hh/GLI and mTOR signaling.
Methods
Reagents
We purchased antibodies against SHH (rat mAb) and
Notch1 (rabbit mAb) from Abcam (Cambridge, UK), anti-
bodies against GLI1 (mouse mAb) from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA, USA), antibodies against
β-catenin (mouse mAb) from BD Transduction Laborator-
ies (Lexington, KY, USA), antibodies against CD133
(mouse mAb clone AC133) and CD44 (mouse mAb clone
DB105) from Miltenyi Biotec (Cologne, Germany), respect-
ively. We obtained. GANT61 (2,2′-[[Dihydro-2-(4-pyridi-
nyl)-1,3(2H,4H) - pyrimidinediyl]bis(methylene)]bis(N,N-di
methylbenzenamine)), cyclopamine, and rapamycinfrom





Human pancreatic cancer cell lines, Capan-1, PANC-1
and MIA PaCa-2 were purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA)
and cultured in DMEM/F12 medium containing 10 %
fetal bovine serum (Invitrogen, Carlsbad, CA, USA), at
37 °C under a humidified atmosphere of 95 % air and
5 % CO2. We established the Capan-1 M9 cells as de-
scribed previously [10].
Sphere formation assay
Multicellular sphere formation assay
Single-cell suspensions were plated in a 24 well ultra-
low attachment surface culture plate (Corning, NY,
USA) at a density of 1000 cells per well in 0.5 ml
medium and other conditions are same as the previously
described methods for single cell sphere formation [6].
Single cell sphere formation assay
Single-cell suspensions were plated in a 96 well ultra-
low attachment surface culture plate (Corning, NY,
USA) by limiting dilution method at a density of 0.7 cells
per well in 0.1 ml medium and other conditions are
same as multicellular sphere formation assay above.
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Immunofluorescence staining
We fixed the cells in 4 % paraformaldehyde for 10 min
at room temperature followed by permeabilization with
0.2 % Triton X-100 in PBS and blocking with 2 mg/ml
BSA, then incubated them with primary antibodies over-
night at 4 °C. Afterwards, we incubated the cells with
fluorescent-labeled secondary antibodies.
Flow cytometric analysis
Cells were stained with the mouse anti-human CD133
mAb (allophycocyanin (APC)-conjugated) and the mouse
anti-human CD44 mAb (R-phycoerythrin (PE)-conju-
gated) and analyzed with a FACSAria II flow cytometer
(Becton Dickinson, Franklin Lake, NJ, USA) [5].
MTT cell viability assay
2 × 103 cells were seeded in a 96-well plate and treated
with the inhibitors for three days. Then the cell viability
was determined by MTT assay [5].
siRNA transfection and Real-time quantitative PCR
(RT-PCR)
GLI1-siRNA was purchased from ambion (Life Tech-
nologies, CA, USA) and transfected using Lipofecta-
mine™ RNAiMAX transfection reagent according to the
manufacturer’s instructions.
Briefly, single cell suspension containing 2 × 105 cells
in 2 ml of DMEM/F12 with 10 % FCS were mixed with
RNAi duplex consisting of 50 pmol siRNA and 3.5 μl
RNAiMAX reagent and plated in a well of 6 well plate
(first/reverse transfection). Cells were cultured for 48 h,
and then the medium was changed with DMEM/F12
with 10 % FCS containing 50 pmol siRNA and 3.5 μl
RNAiMAX reagent (second/forward transfection). Incu-
bation was continued for 48 h and cells were used for
experiments.
Total RNA was extracted using TRIzol (Invitrogen,
CA, USA) and Direct-zol RNA MiniPrep Kit (Zymo
Research, CA, USA) according to the manufacturer’s in-
structions. For messenger RNA quantification, primers,
probes and 2× Taqman Universal PCR Master Mix were
obtained from Applied BiosystemsTM (Life Technologies,
CA, USA). RT-PCR was performed in accordance with
the manufacturer’s instructions, using a StepOne Real-
time PCR system (AppliedBiosystems, CA, USA).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used for normalization.
Two dimensional culture colony formation assay
Single cell suspension was prepared and cells were
seeded into100 μl of DMEM/F12 containing 10 % FCS
in single wells on 96-well plates using a FACS Aria II
system. Seven days after seeding, the number of wells
containing colonies were measured.
DNA-microarray analysis
Total RNA was extracted using an RNeasy extraction kit
(Qiagen, Hilden, Germany). The cDNA was amplified,
labeled, and hybridized to a 44 K Agilent 60-mer oligo
microarray according to the manufacturer’s instructions.
All hybridized microarray slides were then scanned by
an Agilent scanner. Relative hybridization intensities and
background hybridization values were calculated using
Agilent Feature Extraction Software.
In vivo treatment of xenograft with GANT61 and
rapamycin
The animal study was approved by the Committee on
the Use of Live Animals for Teaching and Research of
Kagoshima University. BALB/c nu/nu (nude) mice were
purchased from CLEA Japan (Tokyo, Japan). For in vivo
treatment of GANT61 and/or rapamycin, nude mice
were randomly assigned to four groups at two weeks
after s.c. injection of Capan-1 M9 cells (5 x105 cells per
injection). Mice received treatments of 40 mg/kg/day
GANT61 (i.p.), 1 mg/kg/day rapamycin (i.p.), or their
vehicle (20 % ethanol in corn oil for GANT61and 5 %
PEG400, 5 % Tween-80 and 4 % ethanol for rapamycin,
i.p.) 3 times a week for 25 days. The tumors were mea-
sured after a 4 or 5-day interval; the tumor volume was
calculated as follows: tumor volume = length × width2/2.
Statistical analyses
The results are expressed as the mean ± standard devi-
ation (s.d.). We evaluated comparisons between the aver-
ages of two groups using a two-tailed Student’s t-test.
We considered P < 0.05 to be statistically significant.
Results
Hedgehog signaling components are expressed in
pancreatic cancer cells
In order to confirm the expression of Hh signaling com-
ponents, we performed immunofluorescence staining of
pancreatic cancer cell lines with anti-SHH or anti-GLI1
antibodies. Three typical cell lines of pancreatic cancer
(PANC 1, MIA PaCa-2, and Capan-1) and one subline
established in our laboratory (Capan-1 M9 [10], see 3.2)
showed positive staining with anti-SHH and anti-GLI1
antibodies (Fig. 1). It is important that GLI1 staining re-
vealed the nuclear dominant pattern, because GLI1/2,
which is the final mediator of the pathway, accumulates
in the nucleus and activates the transcription of target
genes upon the activation of Hh signaling [7]. In con-
trast, we could not confirm the nuclear staining of β-
catenin or Notch (cytoplasmic tail) (Additional file 1:
Figure S1B), although frequent activation of these signals
in pancreatic cancer and their crucial functions in CSCs
are reported [7]. These molecules act as the mediators
for Wnt/β-catenin or Notch signaling by similar
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mechanisms, i.e., nuclear translocation and target gene
activation. No staining of β-catenin nor Notch in the
nucleus may correlate with the ineffectiveness of the in-
hibitors for Wnt/β-catenin and Notch signaling path-
ways on pancreatic cancer cells [6] (Additional file 1:
Figure S2).
Signaling in the Hedgehog pathway regulates pancreatic
cancer stem cell characteristics
To evaluate the significance of Hh signaling in the main-
tenance of CSC properties, we examined the effect of Hh
signaling inhibitors on pancreatic cancer cell line Capan-
1 M9. This subline is a highly migratory and invasive sub-
line selected from the human pancreatic cancer cell line,
Capan-1, and displays an elevated expression of CD133
(approximately 90 % of the cells express CD133) [10] (also
see Additional file 1: Figure S3). We used this subline as
an in vitro CSC model system for CD133+ pancreatic can-
cer stem-like cells, because CD133+ Capan-1 cells were
identified as a population of cancer stem-like cells [6, 11].
First, we examined the effect of Hh inhibitors on the
sphere formation (multicellular sphere formation assay)
of Capan-1 M9 cells. Spheroid formation is an index of
the cells’ self-renewal capacity, which is a major property
of stem cells [12]. Cancer stem-like cells have been cul-
tured under bFGF (+) EGF (+) and serum-free condi-
tions to investigate their sphere-forming ability [2, 13].
Under stem cell growth conditions, Capan-1 M9 cells
formed spheres that reached 140 μm in diameter after
8 days (Fig. 2a). Treatment with inhibitors, cyclopamine
and GANT 61 at 20 μM, significantly reduced both the
size and number of spheres formed. Spheres that
were larger than 100 μm in diameter are depicted in
Fig. 2b. Cyclopamine reduced the sphere number by
half: in contrast, GANT61 actually abolished the for-
mation of spheres of this size. These results indicate
that Hh signaling is essential for the self-renewal of
CD133+ pancreatic cancer cells as exhibited by the
sphere formation and the Hh/GLI inhibitor, GANT61,
reduced more efficiently than the Hh/SMO inhibitor,
cyclopamine.
Our previous study [6] (Additional file 1: Figure S2)
and others [14] have reported that the Hh/SMO inhibi-
tor cyclopamine reduces the CD133 expression in
pancreatic cancer cells. To examine whether or not the
Hh/GLI inhibitor GANT61 also reduces CD133 expres-
sion, we treated Capan-1 M9 cells with GANT61 for
3 days and then analyzed them by FACS. Treatment
with GANT61 reduced the amount of CD133+ cells in
the Capan-1 M9 cells in a concentration-dependent
manner (Fig. 2c and Additional file 1: Figure S3),
highlighting that the reduction of CD133 expression
is a common feature of Hh inhibitors. The signifi-
cance of Hh/GLI signaling to maintain CSC proper-
ties was also supported by the analysis of stem cell
markers. Again, GANT61 induced greater reduction
in the CD133 content (percentage) of pancreatic can-
cer cells than cyclopamine (compare Fig. 2c with
Additional file 1: Figure S2).
Collectively, these results demonstrate that Hh signal-
ing plays a critical role to maintain CSC-like properties
of pancreatic cancer cells. Furthermore, the Hh/GLI
Fig. 1 Immunofluorescence detection of the ligand and mediator of hedgehog (Hh) signaling in a culture of pancreatic cancer cells. GLI1: green,
sonic hedgehog (SHH): red, DAPI: blue. Scale bar: 100 μm. The experiment was repeated three times and the representative results were indicated.
Negative controls, the staining only with secondary antibodies, are depicted in Additional file 1: Figure S1A
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inhibitor, GANT61, was more efficient in blocking the
function of these cells than the Hh/SMO inhibitor,
cyclopamine.
CD133+ pancreatic cancer cells are sensitive to hedgehog/
GLI inhibitor GANT 61
It has been reported that Hh signaling is blocked more
efficiently by GANT61 at the level of GLI1/GLI2, which
in turn induces DNA damage and cell death in human
colon carcinoma cells, compared with the SMO inhibitor
cyclopamine [15]. The effects of GANT61 on the cell
viability of CD133+ pancreatic cells was examined. We
treated Capan-1 M9 cells with either cyclopamine or
GANT61 for 3 days prior to performing an MTT cell
viability assay. The cell viability of Capan-1 M9 cells was
reduced by GANT61 in a concentration-dependent
manner (Fig. 3b), whereas cyclopamine did not have any
detectable effect on viability (Fig. 3a). Thus, targeting
GLI1/GLI2 (GANT61) would induce a greater effect on
CD133+ cell viability than targeting SMO (cyclopamine).
The SMO-agonist SAG does not stimulate the sphere
formation
To evaluate the impact of SMO stimulation on sphere
formation of CD133+ cells, we apply the SMO-agonist
SAG to Capan-1 M9 cells. The treatment of Capan-
1 M9 cells with 20 μM GANT61 in the single cell sphere
formation assay actually abolished the formation of
spheres (Fig. 3c), showing a similar result observed in
multicellular sphere formation assay (see Fig. 2b). In
contrast, the treatment of Capan-1 M9 cells with 1
nM – 1 μM SAG does not affect the sphere forma-
tion significantly (Additional file 1: Figure S4). This
may indicate that Hh/SMO signaling is less important
to maintain pancreatic CSC-like properties or the sig-
naling is saturated without stimulation by SAG.
PANC-1 cells are resistant to GANT61 compared to
CD133+ pancreatic cancer cells
On the other hand, we examined the effect of GANT61
on another pancreatic cancer cell line PANC-1, which is
Fig. 2 Inhibition of hedgehog (Hh) signaling reduced the self-renewal as evidenced by sphere formation and the expression of stem cell marker
CD133 of pancreatic cancer cells. a Representative photographs of Capan-1 M9 spheres cultured in a stem cell culture medium in the absence or
presence of 20 μM of inhibitors, cyclopamine or GANT61. Scale bar: 100 μm. b The effects of cyclopamine and GANT61 on the number of spheres.
Primary spheres were cultured in triplicate and the sphere numbers that were larger than 100 μm in diameter were counted per well. The results
are presented as the mean and s.d. of triplicates obtained in 1 representative experiment out of 2.*P < 0.05. c The effects of GANT61 on
the frequency of CD133+ cells. The results are presented as percentages of control values in untreated cells, showing the mean and s.d.
of triplicates obtained in 1 representative experiment out of 2
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reported as a cyclopamine resistant cell line [16].
Although we have not identified the cancer stem cell
marker for PANC-1 cells, PANC-1 has been shown to
form tumors in immunodeficient mice (Additional file 1:
Table S1), indicating that it contains the cells with CSC-
like properties. The effects on cell viability of PANC-1
cells were much modest than those on Capan-1 M9
cells, though the reduction of viability in PANC-1
cells was still statistically significant at 30 μM by
GANT61 (P < 0.01, Fig. 3b).
To analyze the effects of GANT61 on the sphere for-
mation of PANC-1 cells, we cultured PANC-1 cells in
96-well plates using the limiting dilution method (single
cell sphere formation assay) [12]. When PANC-1 cells
are plated in 24 wells with 1000 cells per well, which is
the plating condition in multicellular sphere formation
assay, they form a large aggregate (Additional file 1:
Figure S5A). Thus the determination of sphere-forming
ability by the multicellular method is not possible for
PANC-1 cells. Under stem cell culture conditions,
PANC-1 cells formed spheres of 200 μm in diameter
after 8 days (Additional file 1: Figure S5B). The
administration of 20 μM GANT61 did not reduce the
number of spheres (Fig. 3d). A higher concentration of
GANT61 (40 μM) is required to inhibit the sphere for-
mation of PANC-1 cells (Fig. 3d). Therefore, it is sug-
gested that the cancer stem-like cells in PANC-1 show
much greater resistance to GANT61 than those in the
Capan-1 M9 cells in a sphere formation assay.
GLI1 knockdown reduces the sphere formation and cell
viability of CD133+ pancreatic cancer cells
To confirm that GLI is indeed the important and key
molecules to maintain CSC-like properties of pancreatic
cancer cells, we knocked down GLI1 in Capan-1 M9
cells. GLI2 expression was not detectd in this cell line by
RT-PCR (data no shown). The transfection of siRNA
against GLI1 significantly reduced the mRNA level
(Fig. 4a). GLI1 knockdown reduces the sphere formation
and cell viability of Capan-1 M9 cells (Fig. 4b and c). In
contrast, the colony formation in 2 dimensional culture
was not reduced by the transfection of GLI-siRNA
(Fig. 4d). These results support the notion that that GLI
is the key molecules in the Hh pathway to maintain
CSC-like properties of pancreatic cancer cells, and
exclude GANT61-mediated off target or simply toxic
effects in the sphere formation assay.
In addition, DNA-microarray analysis revealed that
GLI1 is upregulated in spheres (Additional file 1:
Figure S6). This also supports the significant function
of GLI in sphere formation.
Combination treatment with the hedgehog/GLI inhibitor
and the mTOR inhibitor
We demonstrated that Hh/GLI signaling plays a critical
role in maintaining the CSC-like properties and the via-
bility of pancreatic cancer cells. Hence, targeting the
pathway by GANT61 is a potentially effective method to
treat the pancreatic CSCs. To provide a robust thera-
peutic approach against the resistant cell population
such as PANC 1 cells, we tried the combination treat-
ment of pancreatic cancer cells with the mTOR inhibitor
rapamycin. A single treatment of 20 μM GANT61 or
100 nM rapamycin did not reduce the number of
spheres in PANC-1 cells. In contrast, the combination of
these two inhibitors strongly reduced the sphere forma-
tion of PANC-1 cells (Fig. 4a). These results provide the
proof that double blockage of Hh/GLI and mTOR
signaling strongly suppress the self-renewal of cancer
stem-like cells which show a low sensitivity to GANT61.
In addition, this combination improved the effect of
inhibitors on the viability of the PANC-1 cells. After a
single treatment with either 40 μM GANT61 or 100 nM
rapamycin, 40–50 % of the cells remained viable. Com-
bination treatment with the two inhibitors reduced cell
viability to approximately 15 % (Fig. 4b). When we
Fig. 3 The hedgehog (Hh)/GLI inhibitor GANT61 reduced the
viability and sphere formation of pancreatic cancer cells; PANC-1
is a less sensitive cell line. a, b The hedgehog (Hh)/GLI inhibitor
GANT61, but not the Hh/SMO inhibitor cyclopamine, significantly
reduced the viability of pancreatic cancer cells. The results are
presented as percentages of control values in untreated cells,
showing the mean and standard deviation (s.d.) of 4 replicates
obtained in 1 representative experiment out of 3. Closed circle:
Capan-1 M9. Open circle: PANC-1. c GANT61 reduced the sphere
formation of Capan-1 M9 cells in a single cell sphere formation
assay. We determined the number of spheres formed per 96-well
plate in triplicate. All data are mean and s.d. in 1 representative
experiment out of 2. d GANT61 reduced the sphere formation of
PANC-1 cells at a higher concentration. The results are presented
as (c). *P < 0.05
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added a low concentration of gemcitabine, a conven-
tional anticancer drug, to this combination, viable cells
virtually disappeared, whereas the same concentration of
gemcitabine alone only reduced the cell viability to ap-
proximately 50 %.
We confirmed the effect of combination treatment
of GANT61 and rapamycin also in Capan1M9 cells
(Additional file 1: Figure S7A). In addition, in vivo treat-
ment of the combination of GANT61 and rapamycin on
xenograft tumors derived from this cell line suppressed
tumor growth (Additional file 1: Figure S7B).
The combination treatment with the Hh/GLI inhibitor
GANT61 and the mTOR inhibitor rapamycin strongly
reduced the sphere formation and cell viability of
pancreatic cancer cells, suggesting the possibility of
controlling pancreatic CSCs by blocking both these
signaling pathways.
Discussion
The discovery and development of CSC-targeting ther-
apies are dependent on the identification of key mole-
cules controlling the unique properties of CSC
populations. In this study, we investigated the signifi-
cance of Hh signaling for the maintenance of CSC-like
properties using typical cell lines of pancreatic cancer.
We found that the inhibitors of Hh signaling reduced
self-renewal ability, as indicated by sphere formation and
the expression of a CSC marker CD133, demonstrating
the crucial function of the Hh pathway in pancreatic
CSCs. Furthermore, we demonstrated that the Hh/GLI
inhibitor GANT61 is more efficient in reducing the
CSC-related properties than the Hh/SMO inhibitor
cyclopamine, indicating GLI as a key molecule in the
pathway.
A spheroid formation is a major property of CSCs
under serum-free culture conditions, and used fre-
quently to show the self-renewal ability of CSCs in vitro.
CSC marker is another method to recognize CSCs, and
important in clinical analysis. The up-regulation of
CD133, a marker of CSCs, in pancreatic cancer corre-
lates with poor prognosis of patients [17]. There was a
significant correlation between CD133 expression and
the tumorigenicity, chemoresistance, and migration and
invasion ability of Capan-1 cells [10]. After the treatment
with gemcitabine, CD133+ cell content (percent) is in-
creased in Capan-1 cells. This may be caused by a higher
capacity of CD133+ cells to resist the anticancer drag for
the standard therapy. In contrast, the inhibitors of Hh
signaling reduce the content of CD133+ cells. GANT61
showed 80 % reduction at high concentration while the
reduction by cyclopamine reached plateau around 50 %.
In addition, the cell viability of Capan-1 M9 cells was re-
duced linearly by GANT61, whereas cyclopamine did
not have any detectable effect. Therefore, the viability of
CD133+ cells, which would be indicated as a multiplica-
tion of CD133+ cell content and the total cell viability
including both CD133+ and CD133− cells, is reduced
much more efficiently by GANT61 than cyclopamine.
Not only in sphere formation but also in the analysis of
CSC marker CD133, the Hh/GLI inhibitor in blocking
the critical function of Hh signaling in CSC-like cells
was more efficient than the Hh/SMO inhibitor.
Multistage development of pancreatic cancer in mouse
models is not affected by the deletion of the SMO, which
is essential for the transduction of the canonical Hh signal
from the extracellular ligand [18]. According to the report,
autocrine SHH-Ptch-SMO signaling is not required for
cancer progression and alternative mechanisms keeping
Fig. 4 GLI1 knockdown reduces the cell viability and sphere formation
of pancreatic cancer cells but not the colony formation in two
dimensinal culture. a GLI1 expression after GLI1-si RNA transfection
measured by RT-PCR. b Reduction of cell viability by GLI1-siRNA. Cells
were transfected for 96 h, then followed by MTT assay. The results are
presented as percentages of control values in untreated cells, showing
the mean and s.d. of 4 replicates obtained in 1 representative
experiment out of 2. c Inhibition of sphere formation by GLI1-siRNA.
Cells were transfected for 96 h, then followed by single cell sphere
formation assay. The results are presented as in Fig. 3c. d Effect of
GLI1-siRNA on the colony formation in two-dimensional culture. Cells
were transfected for 96 h, then single-cell suspensions were plated in
96 well plate as 1 cell/well. After 7 days incubation, the number of
colonies formed in a plate were counted. The results are presented
as the mean and s.d. of 3 replicates obtained in 1 representative
experiment out of 2. *P < 0.05
Miyazaki et al. Molecular Cancer  (2016) 15:49 Page 7 of 10
the expression of GLI target genes exist in pancreatic
cancer cells. Those mechanisms, namely the noncanonical
activation pathway of GLI, may underlie the ineffective-
ness of Hh/SMO inhibitors. Hh/SMO inhibitors cannot
block the noncanonical Hh signal. It is important that dis-
appointing results have been reported in the clinical trials
of Hh/SMO inhibitors for pancreatic cancer [7]. Collect-
ively, the key molecules controlling the properties of pan-
creatic CSCs in the Hh pathway are GLI transcription
factors, and the correlation between SMO and CSC-like
properties is rather restricted.
On the basis of the above notion that GLI transcription
factors are the key molecule in the Hh pathway, we pro-
posed a novel combination treatment on pancreatic CSCs
with the Hh/GLI inhibitor GANT61 and the mTOR in-
hibitor rapamycin. Targeting the Hh pathway by GANT61
is a potentially effective method, however the sensitivity to
GANT 61 varies among cell lines, suggesting that some
pancreatic cancer cell populations may show the resist-
ance to GANT61 in a manner similar to PANC-1 cells.
GLI and mTOR are two key molecules in the different sig-
naling pathways, therefore, will show synergistic effect. As
expected, the combination treatment effectively reduced
the sphere formation and cell viability of PANC-1, the
inhibitor-resistant cell line. This novel combination
would improve the efficacy and the applicability of
therapeutic treatments, much more than GANT61
single treatment [19] or the combination treatment of
rapamycin with Hh/SMO inhibitors [13, 20].
Several studies have reported the molecular interaction
of Hh and mTOR signaling, suggesting possible mecha-
nisms of synergistic effects. Recently the crosstalk
between the PI3K/Akt/mTOR and Hh pathways, which
is mediated by S6 kinase (S6K), was described in esopha-
geal adenocarcinoma [21] and in PTEN-deficient glio-
blastoma [22]. S6 kinase S6K1 is activated downstream
of the PI3K/Akt/mTOR pathway and phosphorylates
GLI1, resulting in SMO-independent noncanonical GLI1
activation. In these tumors, simultaneous inhibition of
the Hh pathway by an Hh/SMO inhibitor, and mTOR/
S6K signaling by PI3K and/or mTOR inhibitor showed
enhanced efficacy by avoiding the redundancy of canon-
ical and noncanonical GLI activation (Fig. 5). On the
other hand, induction of apoptosis by the treatment of
GANT61 and PI103, a PI3K/mTOR inhibitor, shows
synergistic effect but the signals are mediated through dif-
ferent effector molecules in rhabdomyosarcoma. GANT61
single treatment upregulates the proapoptotic protein
NOXA while PI103 single treatment upregulates another
proapoptotic protein BMF [23]. This finding cannot be
explained only by the crosstalk between S6K and GLI,
suggesting existence of other mechanism. In our experi-
ments, Hh and mTOR inhibitors showed different effect
on CD133 expression (Fig. 2c and Additional file 1:
Figure S2). This result also suggests the existence of
mTOR specific function, not via GLI activation by
S6K (Additional file 1: Figure S1). Further analysis
will clarify the precise mechanism of synergistic effect
in pancreatic CSCs.
Conclusions
We investigated the significance of Hh/GLI signaling in
pancreatic CSCs to maintain their stemness-related
properties. On the basis of the identification of this key
molecule, we proposed and demonstrated a novel com-
bination treatment using the Hh/GLI inhibitor GANT61
with mTOR inhibition. This combination will provide an
efficient approach to control CSCs in pancreatic cancer
and will improve the therapeutic options for this devas-
tating disease.
Additional file
Additional file 1: Figure S1. Staining of Capan-1 M9 cells without first
antibodies as negative controls (A) and with antibody against β-catenin
or Notch 1 (intra cellular domain: NICD) (B). Scale bar: 100 μm. Similar
results were obtained in the staining of PANC-1, MIA PaCa-2 and Capan-1
Fig. 5 a The hedgehog (Hh)/GLI inhibitor GANT61 (20 μM)
in combination with the mTOR inhibitor rapamycin (100 nM)
effectively reduced the sphere formation of PANC-1 cells.
The results are presented as in Fig. 3c. b The hedgehog (Hh)/GLI
inhibitor GANT61 (40 μM) in combination with the mTOR inhibitor
rapamycin (100 nM) effectively reduced the viability of PANC-1 cells.
The results are presented as in Fig. 3 a and b. *P < 0.05
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cells (data not shown). The experiment was repeated three times and the
representative results were indicated. Figure S2. The effects of signaling
inhibitors on the frequency of CD133+ cells and the viability of pancreatic
cancer cells. We treated Capan-1 M9 cells with the inhibitors at the indicated
concentration for 3 days, then determined the frequency of CD133+ cells
and their cell viability by flow cytometry and the MTT assay, respectively.
The results are presented as percentages of control values in untreated cells,
showing the mean and standard deviation (s.d.) of 4 replicates obtained in
1 representative experiment. Figure S3. The effects of GANT61 on the
surface markers and the shape of Capan-1 M9 pancreatic cancer cells.
(A) Flow cytometric analysis of CD133 and CD44 expression on Capan-1 M9
cells treated with or without GANT61. We treated the Capan-1 M9 cells for
3 days, then analyzed them. (B) Representative photographs of Capan-1 M9
cells untreated and treated with GANT61. GANT61 treatment induced a
morphologic change of the Capan-1 M9 cells. This may correlate with the
increased baseline level in the flow cytometric analysis of GANT61 treated
cells shown in (A), which reflect the changes in the structure of the cell
surface. Scale bar: 100 μm. Figure S4. The SMO-agonist SAG does not
stimulate the sphere formation in Capam1M9 cells. We treated Capan-1 M9
cells with indicate4d concentration of SAG during sphere formation and
determined the number of spheres formed per 96-well plate in triplicate.
All data are mean and s.d. in 1 representative experiment out of 2.
Table S1.Tumorigenesis of pancreatic cancer cell lines in NOD/SCID
mice. Figure S5. The limiting dilution method is necessary to analyze
the sphere-forming ability of PANC-1 cells. (A) PANC-1 cells form
large aggregates in the multicellular sphere formation assay. We
plated single-cell suspensions (103 cells in 0.5 ml) in 24 wells and cultured
them. Representative photographs from day 2. (B) Representative
photographs of PANC-1 spheres in the single-cell sphere formation
assay. We plated single-cell suspensions (1.2 cells in 100 μl) in 96
wells and cultured them for 8 days. Scale bar: 100 μm. Figure S6.
A heatmap of the DNA microarray demonstrates upregulation of GLI1
expression in spheres of Capan-1 M9 cells under stem cell culture
condition. M9: Capan-1 M9 cells in two-dimensional culture with
10 % FCS, M9 Sphere: Capan-1 M9 spheres formed in a stem cell
culture medium. Figure S7. (A) The hedgehog (Hh)/GLI inhibitor
GANT61 (10 μM) in combination with the mTOR inhibitor rapamycin
(10 nM) effectively reduced the sphere formation of Capan-1 M9
cells. The results are presented as in Fig. 3c. (B) The hedgehog
(Hh)/GLI inhibitor GANT61 in combination with the mTOR inhibitor rapamycin
impairs in vivo growth of xenografted pancreatic carcinoma in nude mice.
Tumor growth of Capan-1 M9 xenografts which were treated with vehicle,
40 mg/kg of body weight, 1 mg/kg of body weight, or combination. Tumor
volume was shown as the mean and SD from 5 mice (10 tumors) from each
group. * P< 0.05. Figure S8. A schematic representation of the possible
mechanism(s) underlying the synergistic effect of double blockage of Hh
and mTOR signaling. The decoupling of GLI activation from SHH-PTCH-SMO
signaling and/or the redundancy of canonical and noncanonical GLI activation
may underlie the ineffectiveness of Hh/SMO inhibitors. This makes GLI as the
key molecule in Hh pathway. The difference in the effect of Hh/GLI inhibitors
(which reduces CD133+ cell content) and the mTOR inhibitor (which does not
reduce CD133+ cell content) suggests that the mTOR function is not mediated
only by S6K. Assuming the specific function of mTOR (*) will explain
the different effect. (PDF 466 kb)
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